| Literature DB >> 35845029 |
Ankie Reumkens1,2,3, Prapto Sastrowijoto4, Heike I Grabsch5,6, Danny Goudkade4, Chantal le Clercq1,3, Minke Bakker1, Eric Keulen3, Rogier de Ridder1, Wouter W de Herder7, Bjorn Winkens8,9, Silvia Sanduleanu1,6, Judith de Vos-Geelen6,10, Ad Masclee1,2.
Abstract
Background and study aims Neuroendocrine neoplasms (NEN) account for a small number of colorectal neoplasms. Endoscopic detection is essential for diagnosis, treatment and follow-up. Little is known about incidence of NENs in colonoscopy populations or the relationship between clinical, endoscopic and histopathologic features. We evaluated epidemiology, endoscopic and clinical characteristics of colorectal NENs in a population-based cohort. Patients and methods Medical records of NEN cases were cross-linked with the national pathology database from January 2001 to December 2015, in South Limburg County, the Netherlands, covering four endoscopy units. Senior pathologists reviewed and classified NENs using World Health Organization 5th edition (2019) guidelines. Results The number of colorectal NEN diagnoses was stable over time with 0.6 NEN per 1,000 patients. A total of NENs were detected in 85 patients: 65 neuroendocrine tumors (NETs) and 20 poorly differentiated neuroendocrine carcinomas (NECs). Rectal NETs were usually small sessile/submucosal lesions with yellowish (lipoma-like) color. Colonic NETs were larger sessile/submucosal lesions with darker color compared to background. Colorectal NECs presented as large, dark-colored lesions with ulcerated/necrotizing areas. Conclusions Our population-based data point to a stable and low incidence of 0.6 NEN per 1,000 patients in the Netherlands. Rectal NETs mainly present as small sessile yellowish lesions. Colonic NETs present as larger and darker lesions than background mucosa and NECs as darker lesions than background with ulceration/necrosis. Standardized endoscopic characterization of colorectal NENs is necessary to improve recognition of these lesions and provide a basis for evidence-based treatment and surveillance recommendations. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2022 PMID: 35845029 PMCID: PMC9286769 DOI: 10.1055/a-1793-9057
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1GEP-NEN nomenclature, 5th ed. WHO classification (2019).
Fig. 2Study flowchart for colorectal NEN.
Fig. 3 Time trends in diagnosis of colorectal NENs.
Characteristics of neuroendocrine tumors.
| Tumor site | |||||
| Colon | Rectum | ||||
| N = 12 | % | N = 53 | % | ||
| Age, mean (years) ±SD (range) | 62 ± 12 (39–79) | 58 ± 10 (33–80) | 0.34 | ||
| Gender, male | 7 | 58.3 | 25 | 47.2 | 0.54 |
| NET grade | 0.089 | ||||
Grade 1 | 11 | 91.7 | 45 | 84.9 | |
Grade 2 | 0 | 0 | 8 | 15.1 | |
Grade 3 | 1 | 8.3 | 0 | 0 | |
| Indication for colonoscopy | 0.55 | ||||
Symptoms | 9 | 75.0 | 41 | 77.4 | |
Screening | 1 | 8.3 | 1 | 1.9 | |
Surveillance | 2 | 16.7 | 11 | 20.8 | |
| Tumor size | |||||
| Median, IQR, mm | 33 (5–40) | 6 (3–9) |
0.006
| ||
| Category |
0.001
| ||||
< 1 cm | 4 | 33.3 | 41 | 77.4 | |
1–2 cm | 0 | 0 | 9 | 17.0 | |
> 2 cm | 8 | 66 | 3 | 5.7 | |
| Tumor site colon | |||||
Cecum | 10 | 83.3 | – | – | – |
Ascending | 0 | 0 | – | – | – |
Transverse | 0 | 0 | – | – | – |
Sigmoid | 2 | 16.7 | – | – | – |
| Endoscopic features | |||||
| Morphology | |||||
Submucosal/sessile lesion | 11 | 91.7 | 53 | 100 | 0.19 |
(Pseudo)depression or donut-shaped | 3 | 25.0 | 15 | 28.3 | 1.00 |
Regular surface | 9 | 75.0 | 51 | 96.2 |
0.040
|
Vessels: prominent, yes | 4/6 | 80.0 | 23 | 23/24 = 95.8 | 0.32 |
Lipoma-like | 2 | 16.7 | 45 | 84.9 |
< 0.001
|
| Color |
0.001
| ||||
Yellowish color | 4 | 33.3 | 45 | 84.9 | |
Darker than background | 8 | 66.7 | 8 | 15.1 | |
| Stage | |||||
Lymph node metastasis | 4 | 33.3 | 3 | 5.7 |
0.018
|
Distant metastasis | 2 | 16.7 | 4 | 7.5 | 0.31 |
Total | 4 | 33.3 | 4 | 7.5 |
0.033
|
| Treatment | |||||
Endoscopy | 2 | 16.7 | 46 | 86.8 |
< 0.001
|
Surgery | 7 | 58.3 | 3 | 5.7 |
< 0.001
|
Surgery + (neo)adjuvant therapy | 1 | 8.3 | 1 | 1.9 | 0.29 |
Palliative therapy | 0 | 0 | 1 | 1.9 | 1.00 |
No treatment | 2 | 16.7 | 2 | 3.8 | 0.51 |
| Resection | |||||
Complete endoscopically | 2 | 16.7 | 46 | 86.8 |
< 0.001
|
Complete surgically
| 8 | 66.7 | 4 | 7.5 |
< 0.001
|
| After complete resection | |||||
Recurrence | 0 |
| 2 |
| |
Metastasis | 1 |
| 3 |
| |
NET, neuroendocrine tumor; IQR, interquartile range.
P < 0.05.
With or without (neo)adjuvant therapy.
No percentages were calculated because follow-up endoscopy or radiology was not completed in all patients.
Characteristics of neuroendocrine carcinomas.
|
| |||||
|
|
|
|
|
| |
| Age, mean (years) ±SD (range) | 69 ± 4 (63–75) | 72 ± 10 (53–86) | 0.54 | ||
| Gender, male | 4 | 80.0 | 8 | 53.3 | 0.60 |
| NEC | |||||
LCNEC | 3 | 60.0 | 9 | 60.0 | 1.00 |
SCNEC | 2 | 40.0 | 6 | 40.0 | 1.00 |
| Indication for colonoscopy | |||||
Symptoms | 4 | 80.0 | 15 | 100 | 1.00 |
Screening | 0 | 0 | 0 | 0 | 1.00 |
Surveillance | 1 | 20.0 | 0 | 0 | 1.00 |
| Tumor size | |||||
Median, IQR, mm | 48 (33–59) | 50 (30–80) | 0.44 | ||
| Category | |||||
< 1 cm | 0 | 0 | 0 | 0 | 1.00 |
1–2 cm | 0 | 0 | 1 | 6.7 | 1.00 |
> 2 cm | 5 | 100 | 14 | 93.3 | 1.00 |
| Tumor site colon | |||||
Caecum | 2 | 40.0 | – | – | – |
Ascending | 1 | 20.0 | – | – | – |
Transverse | 1 | 20.0 | – | – | – |
Sigmoid | 1 | 20.0 | – | – | – |
| Endoscopic features | |||||
| Morphology | |||||
Submucosal lesion |
0
| 0 |
0
| 0 | |
(Pseudo)depression | 4 | 80.0 | 13 | 86.7 | 1.00 |
Irregular surface | 4 | 80.0 | 13 | 86.7 | 1.00 |
Regular surface | 1 | 20.0 | 2 | 13.3 | |
Ulceration/necrosis | 4 | 80.0 | 13 | 86.7 | 1.00 |
Semi-circular | 3 | 60.0 | 5 | 33.3 | 0.35 |
Stenosis | 0 | 0 | 5 | 33.3 | 0.27 |
| Color | |||||
Yellowish color | 0 | 0 | 0 | 0 | |
Darker than background | 5 | 100.0 | 15 | 100.0 | |
| Stage | |||||
Lymph node metastasis | 1 | 20.0 | 3 | 20.0 | 1.00 |
Distant metastasis | 2 | 40.0 | 8 | 53.3 | 0.61 |
Total | 3 | 60.0 | 9 | 60.0 | 1.00 |
| Treatment | |||||
Endoscopy | 0 | 0 | 1 | 6.7 | 1.00 |
Surgery | 2 | 40.0 | 4 | 26.7 | 0.58 |
Surgery + (neo)adjuvant therapy | 1 | 20.0 | 1 | 6.7 | 0.41 |
Palliative therapy | 0 | 0 | 6 | 40.0 | 1.00 |
No treatment | 2 | 40.0 | 3 | 20.0 | 0.38 |
| After complete resection | |||||
Recurrence | 1 |
| 1 |
| |
Metastasis | 2 |
| 4 |
| |
SD, standard deviation; NEC, neuroendocrine carcinoma; LCNEC, large cell neuroendocrine carcinoma; SCNEC, small cell neuroendocrine carcinoma; IQR, interquartile range.
With or without (neo)adjuvant therapy.
No percentages were calculated because follow-up endoscopy or radiology was not completed in all patients.
Fig. 4Macroscopy of rectal NETs.
Fig. 5 Macroscopy of colonic NETs.
Fig. 6Macroscopy of colorectal NEC (LCNEC vs SCNEC).
Fig. 7 Survival of patients with colorectal NET vs NEC, corrected for age and gender.